Further investigations are warranted to explore the potential of SOS1 PROTACs in suppressing BCR–ABL+ CML and to elucidate the underlying mechanisms. This evidence concerns the gene SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive.